Researcher
Kim De Keersmaecker
- Disciplines:Cancer biology
Affiliations
- Laboratory for Disease Mechanisms in Cancer (Division)
Responsible
From1 Oct 2016 → Today - Laboratory for Disease Mechanisms in Cancer (Division)
Member
From1 Oct 2014 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2013 → 30 Sep 2014 - Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Member
From1 Mar 2009 → 30 Sep 2015
Projects
11 - 20 of 42
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma.From1 Jul 2019 → 30 Jun 2023Funding: Foundations, funds and other with scientific goal
- Contribution of serine synthesis enzyme PSPH in the pathogenesis and therapeutic resistance of T-ALLFrom1 Oct 2018 → 30 Jun 2023Funding: FWO fellowships, Foundations, funds and other with scientific goal
- Clonal evolution and biology of co-operative oncogenic events in acute lymphoblastic leukemia.From1 Oct 2018 → 30 Sep 2023Funding: Fund Recuperation Fiscal Exemption
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myelomaFrom10 Sep 2018 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
- Mass cytometry by time-of-flight: next-generation flow cytometry for multiplexed single cell analysisFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Single-cell omics in high throughput and at spatial resolutionFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Contribution of heterozygous loss of ribosomal protein L5 to glioblastoma pathogenesisFrom18 Nov 2017 → 17 Nov 2020Funding: Nonprofit institution or equivalents
- Exploitation of cancer-associated ribosomal protein mutations for enhanced recombinant protein productionFrom16 Aug 2017 → 31 Mar 2022Funding: FWO Strategic Basic Research Grant
- Bcl-2 inhibition as a new therapeutic opportunity for RPL10 R98S mutant pediatric T-ALLFrom2 Jun 2017 → 1 Jun 2018Funding: Foundations, funds and other with scientific goal
- Metabolic rewiring in cancer: Pharmacological targeting of serine/glycine synthesis addicted cancersFrom24 May 2017 → 15 Dec 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 90
- Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer (12 FEB, 10.1038/s41416-023-02553-y, 2024 )(2024)
Authors: Kim De Keersmaecker, Maarten Lambrecht, Kim Kampen
- Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer(2024)
Authors: Kim De Keersmaecker, Maarten Lambrecht, Kim Kampen
Pages: 568 - 584 - Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.(2024)
Authors: Yani Berckmans, Kim De Keersmaecker, An Coosemans
Pages: 381 - 397 - Drivers of de novo Serine/Glycine synthesis in acute leukemia(2023)
Authors: Paulien Verstraete, Kim De Keersmaecker, Kim Kampen
Pages: 2145 - 2146 - APEX1 Nuclease and Redox Functions are Both Essential for Adult Mouse Hematopoietic Stem and Progenitor Cells(2023)
Authors: Samantha Zaunz, Lukas Lauwereins, Kim De Keersmaecker, Catherine Verfaillie
Pages: 2052 - 2072 - Transcription factor NKX2-1 drives serine and glycine synthesis addiction in cancer(2023)
Authors: Elien Heylen, Paulien Verstraete, Linde Van Aerschot, Tom Venken, David Nittner, Anne Uyttebroeck, Heidi Segers, Diether Lambrechts, Jan Cools, Kim De Keersmaecker, et al.
Pages: 1862 - 1878 - Oncogenic drivers and therapeutic targeting of serine and glycine synthesis in cancer(2023)
Authors: Elien Heylen, Kim De Keersmaecker, Kim Kampen
- SNPs Ability to Influence Disease Risk: Breaking the Silence on Synonymous Mutations in Cancer(2022)
Authors: Xander Janssens, Daniele Pepe, Kim De Keersmaecker
Pages: 77 - 96Number of pages: 20 - HEATR3 variants impair nuclear import of uL18 (RPL5) and drive Diamond-Blackfan anemia(2022)
Authors: Kim De Keersmaecker, Veerle Labarque
Pages: 3111 - 3126 - Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping(2022)
Authors: Jolien De Bie, Sofie Demeyer, Jan Cools, Kim De Keersmaecker, Joris Vermeesch, Johan Maertens, Heidi Segers, Lucienne Michaux, Barbara Dewaele
Pages: 548 - 561
Patents
1 - 3 of 3